Interactive, Live Virtual Webinar


Wednesday, November 12, 2025
1:00 PM - 2:00 PM ET 
12:00 PM - 1:00 PM CT
11:00 AM - 12:00 PM MT
10:00 AM - 11:00 AM PT

Target Audience

This activity is intended for hematologists-oncologists, medical oncologists, PAs, NPs, nurses, and other healthcare professionals engaged in the care of patients with Chronic Lymphocytic Leukemia (CLL).

Learning Objectives

After completing this activity, the participant should be better able to:
  • Explain treatment options including an overview of the latest developments in therapy
  • Identify patients who are candidates for newly approved therapies including BTK inhibitors, alone or in combination, and CAR T-cell therapy 
  • Explain the HCP’s role in preparing the patient for therapy, administering treatment, monitoring for and managing side effects  
  • Discuss long-term follow up and survivorship care planning 

Faculty

Inhye Ahn, MD
Associate Director, Chronic Lymphocytic Leukemia Center
Senior Physician
Assistant Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA 
 
Lauren Berger, MPH
Senior Director, Professional Education and Engagement
Blood Cancer United
Washington, DC 
 
Corinne Hoffman, MS, APRN-CNP, AOCNP 
Nurse Practitioner - Hematology Oncology
The James Comprehensive Cancer Center
The Ohio State University 
Columbus, OH
 
Kerry Rogers, MD
Associate Professor 
Division of Hematology, Department of Internal Medicine 
The James Comprehensive Cancer Center
The Ohio State University 
Columbus, OH
 
 
This activity is provided by Blood Cancer United and Medical Learning Institute Inc.
 

This activity is supported by independent medical education grants from AbbVie Inc. and AstraZeneca Pharmaceuticals.

 

For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: profeducation@LLS.org.

 

Follow Blood Cancer United